Amgen (AMGN) , along with Regeneron (REGN) announced Tuesday they have inked separate deals to expand their anti-cancer research programs. According to TheStreet's Adam Feuerstein, the new deals indicate a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth. Amgen is set to pay $65 million to license rights to a technology from Advaxis in order to develop immunotherapy treatments to help combat brain tumors. Meanwhile, the Regeneron partnership was signed with privately held Adicet Bio and aims to target blood cancers and solid tumors through a form of therapy similar to the those being developed by Juno Therapeutics and Kite Pharma.
More from Video
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.
There is a lot of Apple news to chew on Wednesday.